|
ImmuPharma PLC on Monday said its core anti-infective programme with antifungal and antibacterial candidates is progressing through pre-clinical studies, amid a narrowed loss. The London-based specialist drug discovery and development company said pretax loss narrowed to £2.8 million in 2024 from £3.4 million in 2023. The company reported no revenue, unchanged from 2023. Research & development costs came down to £1.2 million from £2.0 million. ImmuPharma said that its core anti-infective programme with antifungal and antibacterial candidates is progressing through pre-clinical studies. Looking ahead, Chief Executive Officer Tim McCarthy said: ‘We remain focused on bringing our two key late-stage clinical assets, P140 for SLE and CIDP, closer to the market, and securing additional partnering deals for P140 as well as our earlier stage assets, specifically within our anti-infectives program. In closing, we would like to thank our shareholders for their support as well as our staff, corporate and scientific advisers and our partners including CNRS and Avion.’ ImmuPharma shares fell 13% to 2.93 pence each on Monday morning in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
